General Information of Drug (ID: DMK6OFY)

Drug Name
Peginterferon lambda-1a
Synonyms
BMS-914143; IFN lambda, ZymoGenetics/Novo Nordisk; Interferon lambda 1, ZymoGenetics/Novo Nordisk; PEG-IL-29; PEG-rIL-29; Interleukin-29, ZymoGenetics/Novo Nordisk; PEG-IFN lambda, ZymoGenetics/Novo Nordisk; PEG-interferon lambda, ZymoGenetics/Novo Nordisk; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk; Peginterferon lambda-1a, ZymoGenetics/Bristol-Myers Squibb; PEG-IFN lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; PEG-interferon lambda, ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb; Recombinant PEG-interferon lambda-1, ZymoGenetics/Bristol-Myers Squibb; PEGylated IL-29 (HCV infection), ZymoGenetics/Novo Nordisk/Bristol-Myers Squibb
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [2]
Cross-matching ID
DrugBank ID
DB14767
TTD ID
D0T6IN

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-29 (IL29) TTM624L IFNL1_HUMAN Agonist [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-29 (IL29) DTT IFNL1 4.97E-01 -0.01 -0.02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01866930) Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naive Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04354259) Interferon Lambda for Immediate Antiviral Therapy at Diagnosis. U.S. National Institutes of Health.
3 Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C. J Interferon Cytokine Res. 2010 Aug;30(8):591-5.